Antifibrotics - A New Class of Therapies in Rheumatology? Rheumatologists typically manage systemic autoimmune rheumatic diseases (SARD) and associated interstitial lung disease (ILD) with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic https://t.co/IobQagC0ZE

9 yr. study of anti-Ro52 & ILD pts -- 1,026 pts 15% Ro52+: interstitial pneumonia w/ autoimmune 48%, CTD-ILD 13%, idiopathic pulm fibrosis 10%, hypersens pneumonitis 6%, idiopathic ILD 24%. Ro52+ were younger w/ more autoimmune dz, +MSA Abs, ILD progression, death, & lung https://t.co/fuFfnaYIRd

Flow cytometry on Peripheral blood can help patient stratification in RA A cluster rich in TEMRA Terminally Differentiated Effector Memory T Cells is associated with response to treatment and therapeutic decision taking into account showed higher remission 39% vs. 24% Next https://t.co/8ZZ2epf7LK

In #scleroderma pts with cardiac involvement, the presence of ventricular ectopy is assocd w/ ⬆️risk of mortality & SCD. ☝️these arrythmias present late so consider it in pts w/established dse who develop new-onset cardiac symptoms @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/MTDfxevqwb

2025 Update of EULAR RA management recommandation Summary slide inspired from Josef Smolen’s presentation @RheumNow #APLAR25 https://t.co/wRzeX9OIry https://t.co/djrd7O9G9H

Is it #lupus? Interesting study by @escheriKYA et al. showing comparable diagnostic performance of SLERPI (93%) in 🇵🇭 patients vs. SLICC and EULAR/ACR criteria A practical alternative tool that can be used by clinicians in a resource-limited setting 🤔 @RheumNow #APLAR25 https://t.co/xByBkjEr3r

Key takeaways of trabecular bone screening: 📌Complements but doesnt replace BMD/FRAX in fracture risk assessment 📌Dont exclude any lumbar spine unless w/significant change like laminectomy 📌Can use in monitoring untreated pts since TBS declines @RheumNow #APLAR25 https://t.co/bcN83IDDja

Remember! ☝️ Trabecular bone screening should not be routinely used in pre-menopausal women. @RheumNow #APLAR25 #osteoporosis https://t.co/hGMExyDYUX

Japanese retrospective real world study shows antifibrotic use assoc w/ better survival in Pulm Fibrosis-ILD for 1st 3 yrs & improved survival in progressive pulm. fibrosis (PPF) “despite management” (PPF subset prev Rx non-antifibrotic therapy) https://t.co/caiIuhg7j8 https://t.co/N0ST73TMoR

3 yr study of FDA Adverse Event Reporting on anifrolumab shows following AEs- URIs, herpes zoster, infusion reactions, and potential new risks like dyspnea and pyrexia, not in the label. https://t.co/vP2YWGT2vR https://t.co/BruGBtXEBu

Sjogren's Disease Interstitial Lung Disease Dr. Nancy Carteron, a rheumatologist in northern California, discusses interstitial lung disease in Sjogren's disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/lA1vrBiar4